search
Back to results

Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia (ATS12)

Primary Purpose

Amblyopia

Status
Terminated
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Patching
Near activities
Active vision therapy
Control vision therapy
Sponsored by
Jaeb Center for Health Research
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Amblyopia focused on measuring Amblyopia, Vision Therapy, Patching

Eligibility Criteria

7 Years - 12 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 7 to <13 years
  • Amblyopia associated with anisometropia, strabismus (comitant or incomitant), or both at the time of the eligibility examination
  • Visual acuity in the amblyopic eye between 49 and 71 letters inclusive (20/40 to 20/100 inclusive) on the eETDRS
  • Visual acuity in the sound eye of 79 or more letters on the eETDRS (20/25 or better)
  • Inter-eye acuity difference of 15 or more letters (3 or more logMAR lines)
  • At least 800 seconds of arc on the Randot Preschool Stereoacuity Test
  • Previous or current amblyopia treatment with spectacles or contact lenses, patching or atropine is permitted.
  • No myopia more than -6.00 D spherical equivalent in the amblyopic eye
  • Single vision spectacles, if needed, worn for at least 16 weeks or until visual acuity documented to be stable
  • The child has access to a computer on a daily basis (to use the home vision therapy software)

Exclusion Criteria:

  • Previous vision therapy or orthoptics
  • Known skin reactions to patch or bandage adhesives
  • Prior intraocular or refractive surgery
  • Bifocals
  • Constant strabismus at near at the eligibility examination
  • A family member is (or has been) enrolled in this study

Sites / Locations

  • UAB Pediatric Eye Care; Birmingham Health Care
  • Bascom Palmer Eye Institute
  • Indiana University School of Optometry
  • Casey Eye Institute
  • Pediatric Ophthalmology of Erie
  • Family Eye Group
  • Southern College of Optometry

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

Active

Control

Arm Description

2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy

2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy

Outcomes

Primary Outcome Measures

Distribution of Distance Visual Acuity in Amblyopic Eye at 17-week Outcome
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best.
Mean (SD): Distance Visual Acuity in Amblyopic Eye at 17-week Outcome
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best.
Distribution of Change in Amblyopic Eye Visual Acuity From Baseline to 17 Weeks
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity.
Mean (SD) of Change in Amblyopic Eye Visual Acuity From Baseline to 17 Weeks
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity.

Secondary Outcome Measures

Distribution of Fellow Eye Visual Acuity at 17 Weeks
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best.
Mean (SD) of Fellow Eye Visual Acuity at 17 Weeks
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best.
Distribution of Change in Fellow Eye Visual Acuity From Baseline to 17 Weeks
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity.
Mean (SD) of Change in Fellow Eye Visual Acuity From Baseline to 17 Weeks
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity.
Mean (SD) of Intereye Visual Acuity at 17 Weeks
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best.
Mean (SD) of Change in Intereye Visual Acuity From Baseline to 17 Weeks
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity.
Distribution of Randot Preschool Stereoacuity at 17 Weeks
The Randot Preschool Stereotest measures stereopsis from 800 to 40 seconds of arc. This Stereotest is designed as a matching game in which the patient matches pictures in a test booklet wearing special glasses. A subject can fail the pretest (not see any pictures) or can score >800 (the worst), 800, 400, 200, 100, 60, or 40 (the best) seconds of arc. If two shapes are identified correctly the patient progresses to the next lower stereoacuity level. A failed test occurs when the patient cannot identify any shapes.
Distribution of Change in Randot Preschool Steroacuity From Baseline to 17 Weeks
The Randot Preschool Stereotest measures stereopsis from 800 to 40 seconds of arc on patients as young as 2 years of age. This Stereotest is designed as a matching game in which the patient matches pictures in a test booklet wearing special glasses. A subject can fail the pretest (not see any pictures) or can score >800 (the worst), 800, 400, 200, 100, 60, or 40 (the best) seconds of arc. If two shapes are identified correctly the patient progresses to the next lower stereoacuity level. A failed test occurs when the patient cannot identify any shapes.

Full Information

First Posted
December 10, 2007
Last Updated
July 7, 2016
Sponsor
Jaeb Center for Health Research
Collaborators
National Eye Institute (NEI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00587171
Brief Title
Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia
Acronym
ATS12
Official Title
A Randomized Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia in Children 7 to <13 Years Old
Study Type
Interventional

2. Study Status

Record Verification Date
July 2016
Overall Recruitment Status
Terminated
Why Stopped
This study was stopped due to insufficient recruitment.
Study Start Date
April 2008 (undefined)
Primary Completion Date
March 2009 (Actual)
Study Completion Date
October 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Jaeb Center for Health Research
Collaborators
National Eye Institute (NEI)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is comparing the effectiveness of patching combined with active vision therapy plus near activities versus patching combined with control vision therapy plus near activities for moderate amblyopia (20/40-20/100) in 7 to <13 year olds. The primary outcome measure is the proportion of patients with visual acuity of 20/25 or better in the amblyopic eye at the 17-week masked exam. These patients will be considered treatment responders. The primary analysis will consist of a comparison between the 2 treatment groups of the proportion of treatment responders with adjustment for baseline visual acuity. Secondary outcomes are stereoacuity at the 17-week masked exam, mean improvement in visual acuity at the 17-week masked exam, and rate of improvement of visual acuity.
Detailed Description
Patching and atropine have been traditionally used for the improvement of visual acuity in children with amblyopia. Previous studies have shown that these methods of treatment are effective in young children with functional amblyopia. More recently ATS3, a randomized clinical trial of 507 children ages 7-<18, found that part-time patching combined with atropine and near activities improved visual acuity by two or more lines in 53% of the 7 to 12 year olds compared to 25% for optical correction alone. For the 13 to 17 year olds, part-time patching and near activities improved visual acuity by 2 or more lines in 25%, compared to 23% for optical correction alone. While it appears that patching and/or atropine, combined with near activities, can improve visual acuity in some patients ages 7-<18, most patients in the study were left with residual visual acuity deficits. To further improve visual acuity and binocularity in children with amblyopia some eye care providers augment these traditional therapies with vision therapy. Vision therapy is prescribed initially if there is moderate amblyopia with stereopsis. Vision therapy can be added to the treatment regimen once the patient has reached moderate levels of vision loss with stereopsis and if the patient is still not responding to the current treatment and still has moderate amblyopia. It is thought that the best candidates for this type of therapy are those children with a minimum level of stereopsis (at least 800") and without constant strabismus. Those children with no stereopsis would not be able to perform the activities in the later stages of therapy utilizing binocular vision. Vision therapy is a sequence of prescribed activities typically performed on a daily basis at home and weekly in-office, and is directed toward an individual patient's deficient skills. Visual skills are practiced under conditions that provide the patient with feedback. The feedback, along with a gradual increase in the demand of the activities as improvement occurs, enables the patient to improve visual functions such as visual acuity, fixation, accommodation, and vergence skills. There have been case reports and small sample studies that have shown that vision therapy in combination with spectacles and occlusion is effective in improving the visual acuity of patients with amblyopia. Wick et al looked at nineteen patients who were diagnosed with anisometropic amblyopia between the ages of 6 to 49. Seventeen of the patients had moderate amblyopia and two had severe amblyopia, based on the definition of amblyopia used in the Amblyopia Treatment Studies. The patients were treated with a sequence that included spectacle correction, occlusion therapy and both monocular and binocular vision therapy. Thirteen of the seventeen patients with moderate amblyopia had a final visual acuity of 20/25 or better and all of the patients with moderate amblyopia had 20/30 or better final visual acuity. More recent reports on "perceptual learning," an active form of therapy in which amblyopic subjects practice a position-discrimination task, have shown a mean acuity improvement of approximately 30% (two lines) in amblyopic children and adults who had completed occlusion therapy. These studies provide support for the notion that the practice of particular visual skills under conditions that provide the patient with feedback (e.g., vision therapy) may be beneficial in improving the visual performance of amblyopic eyes. The second reason to prescribe active therapy is to enhance or facilitate the effects of occlusion by directly treating the aforementioned deficits found to be associated with amblyopia. Most therapy procedures are designed to remediate specific deficiencies in four main areas: fixation, spatial perception, accommodative efficiency, binocular function and oculomotor control. Lastly, some investigators have suggested that the use of vision therapy may reduce the likelihood of recurrence of the amblyopia. This may be particularly true with anisometropic amblyopia in which vision therapy can be used to improve binocular function.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Amblyopia
Keywords
Amblyopia, Vision Therapy, Patching

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
19 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Active
Arm Type
Active Comparator
Arm Description
2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
Arm Title
Control
Arm Type
Sham Comparator
Arm Description
2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
Intervention Type
Device
Intervention Name(s)
Patching
Other Intervention Name(s)
Coverlet, 3M Opticlude, Ortopad®
Intervention Description
2 hours daily patching
Intervention Type
Procedure
Intervention Name(s)
Near activities
Intervention Description
30 minutes daily near activities at home
Intervention Type
Procedure
Intervention Name(s)
Active vision therapy
Intervention Description
30 minutes of daily at-home active vision therapy and a weekly 45 minute in-office active vision therapy session
Intervention Type
Procedure
Intervention Name(s)
Control vision therapy
Intervention Description
30 minutes of daily at-home control vision therapy and a weekly 45 minute in-office control vision therapy session
Primary Outcome Measure Information:
Title
Distribution of Distance Visual Acuity in Amblyopic Eye at 17-week Outcome
Description
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best.
Time Frame
17 weeks
Title
Mean (SD): Distance Visual Acuity in Amblyopic Eye at 17-week Outcome
Description
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best.
Time Frame
17 weeks
Title
Distribution of Change in Amblyopic Eye Visual Acuity From Baseline to 17 Weeks
Description
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity.
Time Frame
Baseline to 17 weeks
Title
Mean (SD) of Change in Amblyopic Eye Visual Acuity From Baseline to 17 Weeks
Description
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity.
Time Frame
Baseline to 17 weeks
Secondary Outcome Measure Information:
Title
Distribution of Fellow Eye Visual Acuity at 17 Weeks
Description
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best.
Time Frame
17 weeks
Title
Mean (SD) of Fellow Eye Visual Acuity at 17 Weeks
Description
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best.
Time Frame
17 weeks
Title
Distribution of Change in Fellow Eye Visual Acuity From Baseline to 17 Weeks
Description
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity.
Time Frame
Baseline to 17 weeks
Title
Mean (SD) of Change in Fellow Eye Visual Acuity From Baseline to 17 Weeks
Description
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity.
Time Frame
Baseline to 17 weeks
Title
Mean (SD) of Intereye Visual Acuity at 17 Weeks
Description
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best.
Time Frame
17 weeks
Title
Mean (SD) of Change in Intereye Visual Acuity From Baseline to 17 Weeks
Description
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. A difference was calculated as the difference in letters between baseline and outcome with positive difference indicating improvement in acuity.
Time Frame
Baseline to 17 weeks
Title
Distribution of Randot Preschool Stereoacuity at 17 Weeks
Description
The Randot Preschool Stereotest measures stereopsis from 800 to 40 seconds of arc. This Stereotest is designed as a matching game in which the patient matches pictures in a test booklet wearing special glasses. A subject can fail the pretest (not see any pictures) or can score >800 (the worst), 800, 400, 200, 100, 60, or 40 (the best) seconds of arc. If two shapes are identified correctly the patient progresses to the next lower stereoacuity level. A failed test occurs when the patient cannot identify any shapes.
Time Frame
17 weeks
Title
Distribution of Change in Randot Preschool Steroacuity From Baseline to 17 Weeks
Description
The Randot Preschool Stereotest measures stereopsis from 800 to 40 seconds of arc on patients as young as 2 years of age. This Stereotest is designed as a matching game in which the patient matches pictures in a test booklet wearing special glasses. A subject can fail the pretest (not see any pictures) or can score >800 (the worst), 800, 400, 200, 100, 60, or 40 (the best) seconds of arc. If two shapes are identified correctly the patient progresses to the next lower stereoacuity level. A failed test occurs when the patient cannot identify any shapes.
Time Frame
Baseline to 17 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
7 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 7 to <13 years Amblyopia associated with anisometropia, strabismus (comitant or incomitant), or both at the time of the eligibility examination Visual acuity in the amblyopic eye between 49 and 71 letters inclusive (20/40 to 20/100 inclusive) on the eETDRS Visual acuity in the sound eye of 79 or more letters on the eETDRS (20/25 or better) Inter-eye acuity difference of 15 or more letters (3 or more logMAR lines) At least 800 seconds of arc on the Randot Preschool Stereoacuity Test Previous or current amblyopia treatment with spectacles or contact lenses, patching or atropine is permitted. No myopia more than -6.00 D spherical equivalent in the amblyopic eye Single vision spectacles, if needed, worn for at least 16 weeks or until visual acuity documented to be stable The child has access to a computer on a daily basis (to use the home vision therapy software) Exclusion Criteria: Previous vision therapy or orthoptics Known skin reactions to patch or bandage adhesives Prior intraocular or refractive surgery Bifocals Constant strabismus at near at the eligibility examination A family member is (or has been) enrolled in this study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Don W. Lyon, O.D.
Organizational Affiliation
Indiana University School of Optometry
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
David T. Wheeler, M.D.
Organizational Affiliation
Casey Eye Institute
Official's Role
Study Chair
Facility Information:
Facility Name
UAB Pediatric Eye Care; Birmingham Health Care
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
Bascom Palmer Eye Institute
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Facility Name
Indiana University School of Optometry
City
Bloomington
State/Province
Indiana
ZIP/Postal Code
47405
Country
United States
Facility Name
Casey Eye Institute
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Facility Name
Pediatric Ophthalmology of Erie
City
Erie
State/Province
Pennsylvania
ZIP/Postal Code
16501
Country
United States
Facility Name
Family Eye Group
City
Lancaster
State/Province
Pennsylvania
ZIP/Postal Code
17601
Country
United States
Facility Name
Southern College of Optometry
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38104
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
23563444
Citation
Lyon DW, Hopkins K, Chu RH, Tamkins SM, Cotter SA, Melia BM, Holmes JM, Repka MX, Wheeler DT, Sala NA, Dumas J, Silbert DI; Pediatric Eye Disease Investigator Group. Feasibility of a clinical trial of vision therapy for treatment of amblyopia. Optom Vis Sci. 2013 May;90(5):475-81. doi: 10.1097/OPX.0b013e31828def04.
Results Reference
result

Learn more about this trial

Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia

We'll reach out to this number within 24 hrs